|2||5%||Up to $13.20|
|3||10%||Up to $39.60|
|4||15%||Up to $79.20|
|5||20%||Up to $132.00|
invega 6 Mg 28 Extended Release Tablets ingredient paliperidone
Extended release tablet. "PAL 6" printed beige tablet.
497 Item Items
Warning: Last items in stock!
|2||$132.00||Up to $13.20|
|3||$132.00||Up to $39.60|
|4||$132.00||Up to $79.20|
|5||$132.00||Up to $132.00|
PHARMACEUTICAL PROPERTIES 1 List of Subsidiary Materials
Polyethylene oxide 200K Sodium chloride Povidone (K29-32) Stearic acid
(Red) E172 Hydroxyethyl cellulose Polyethylene glycol 3350 Cellulose acetate Hypromellose Titanium dioxide E171 Polyethylene glycol 400
Carnauba wax Iron oxide (black) E172 Propylene glycol
It does not have any known incompatibilities.
6.3. Shelf life
6.4. Special precautions for storage
Store at room temperature below 30 ° C. We are protected from moisture.
6.5. The nature and content of the packaging
28 tablets blister packaging.
Blister: Polyvinyl chloride (PVC) / aluminum push layer coated with polychloro-trifluoroethylene (PCTFE)
6.6. Removal of remaining substances from medical product and other special measures
Unused products or waste materials are classified as' 'Medical Waste Control Regulation' 'and' 'Packaging Waste Control'
4.4. Special use warnings and precautions
As with other antipsychotics, INVEGA should be taken with caution when prescribing INVEGA in patients with known cardiovascular disease or in patients with QT prolongation and other medicines that are thought to prolong QT interval.
Neuroleptic malignant syndrome:
Hyperthermia, Neuroleptic Malign Syndrome (NMS), characterized by muscle rigidity, autonomic instability, altered consciousness and elevation of serum creatinine phosphokinase levels, has been reported to occur with antipsychotic drugs including paliperidone. Additional clinical manifestations may include myoglobulinuria (rhabdomyolysis) and acute renal failure. If signs and symptoms are pointing to a NMS in a patient, all antipsychotic drugs, including INVEGA, should be discontinued.
Drugs with dopamine receptor antagonism have been shown to induce tardive dyskinesia, characterized in particular by language and / or percentage, rhythmic, involuntary movements
They have been associated. If signs and symptoms of tardive dyskinesia occur, discontinuation of all antipsychotic medications, including INVEGA, should be considered.
Glucose-mediated adverse events rarely occur in clinical trials with INVEGA
It has been reported. Clinical monitoring of patients with diabetes or risk factors for the development of diabetes mellitus is recommended.
Paliperidone may cause orthostatic hypotension due to alpha-blocker activity. INVEGA should be used with caution in patients with known cardiovascular disease (eg heart failure, myocardial infarction or ischemia, transmission abnormalities), in patients with cerebrovascular disease or in situations that may cause hypotension (eg dehydration, hypovolemia and antihypertensive medications).
As with other antipsychotic medications, INVEGA should be used with caution in patients who have potentially reduced seizure threshold or have a history of seizures.
Gastrointestinal obstruction potential:
Since INVEGA is not deformed and does not change its shape in the gastrointestinal tract, patients who have previously had severe gastrointestinal constriction (pathological or iatrogenic) or dysphagia or who are suffering from difficulty swallowing tablets should not be randomly applied. In patients known to be constricted, there are infrequent reports of obstructive symptoms associated with ingestion of formulated, controlled release formulation formulations. Due to the controlled release design of the dosage form, INVEGA should only be used in patients who can ingest as a whole (see section 4.2).
Old demented patients:
Conventional and atypical antipsychotic drugs cause an increased risk of death when used in the treatment of elderly patients with dementia-related psychosis.
INVEGA has not been studied in demented elderly patients. Overall mortality
In a meta-analysis of 17 controlled clinical trials, the mortality risk for demented elderly patients using atypical antipsychotic medications including risperidone, aripiprazole, olanzapine, and quetiapine increased compared to placebo.
Cerebrovascular adverse events
In placebo-controlled, clinical trials, the risk of developing cerebrovascular adverse events (cerebrovascular accidents and transient ischemic attacks) increased, including placebo-related deaths, in demented elderly patients treated with some atypical antipsychotic drugs such as risperidone, aripiprazole and olanzapine.
Parkinson's Disease and Lewy Body Dementia:
Patients with Parkinson's Disease or Lewy Body Dementia are at increased risk of developing Neuroleptic Malign Syndrome and increased sensitivity to antipsychotic drugs. For this reason, there is a need for a benefit risk assessment when prescribing antipsychotic drugs, including INVEGA in both groups. Symptoms of this increased sensitivity are postural instability with confusion, obtundation, frequent falls in addition to extrapyramidal symptoms.
Drugs with alpha-adrenergic blocker activity have been reported to cause priapism. Priapism has been reported in postmarketing observations for INVEGA.
Body temperature regulation:
The deterioration of the body's ability to reduce internal body temperature is linked to antipsychotic medications. It is recommended to prescribe INVEGA with caution in patients who may be exposed to excessive exercise, unusual exposure to heat, use of medicines with anticholinergic effects or dehydration of the individual, which can lead to increased internal body heat.
Antiemetic effect was seen in preclinical studies with paliperidone. This effect, if occurring in humans, may overdose some medications or mask such conditions as bowel obstruction, Reye's syndrome, and brain tumors.
Venous thromboembolic event:
Venous thromboembolic events (VTE) have been reported with antipsychotic drugs. Most patients with antipsychotic medication
No customer reviews for the moment.